{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06414798",
            "orgStudyIdInfo": {
                "id": "M24-929"
            },
            "organization": {
                "fullName": "AbbVie",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants.",
            "officialTitle": "A First-in-Human Single Ascending Dose and Mass Balance Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 in Healthy Adult Subjects",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-to-assess-the-safety-tolerability-and-pharmacokinetics-of-abbv-oral-dose-in-healthy-adult-participants"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05-13",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-11-28",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-11-28",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-10",
            "studyFirstSubmitQcDate": "2024-05-10",
            "studyFirstPostDateStruct": {
                "date": "2024-05-16",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-20",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-21",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "AbbVie",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This study will assess the single dose safety, tolerability and pharmacokinetic properties of ABBV-1088 in healthy adult participants"
        },
        "conditionsModule": {
            "conditions": [
                "Healthy Volunteers"
            ],
            "keywords": [
                "Healthy Volunteers",
                "ABBV-1088"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 48,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Group 1- ABBV-1088 Dose A",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive single dose of ABBV-1088 dose A on day 1",
                    "interventionNames": [
                        "Drug: Drug: ABBV-1088"
                    ]
                },
                {
                    "label": "Group 1- Placebo",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive single dose of placebo day 1",
                    "interventionNames": [
                        "Drug: Drug: Placebo for ABBV-1088"
                    ]
                },
                {
                    "label": "Group 2- ABBV-1088 Dose B",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive single dose of ABBV-1088 dose B on day 1",
                    "interventionNames": [
                        "Drug: Drug: ABBV-1088"
                    ]
                },
                {
                    "label": "Group 2- Placebo",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive single dose of placebo day 1",
                    "interventionNames": [
                        "Drug: Drug: Placebo for ABBV-1088"
                    ]
                },
                {
                    "label": "Group 3- ABBV-1088 Dose C",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive single dose of ABBV-1088 dose C on day 1",
                    "interventionNames": [
                        "Drug: Drug: ABBV-1088"
                    ]
                },
                {
                    "label": "Group 3- Placebo",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive single dose of placebo day 1",
                    "interventionNames": [
                        "Drug: Drug: Placebo for ABBV-1088"
                    ]
                },
                {
                    "label": "Group 4- ABBV-1088 Dose D",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive single dose of ABBV-1088 dose D on day 1",
                    "interventionNames": [
                        "Drug: Drug: ABBV-1088"
                    ]
                },
                {
                    "label": "Group 4- Placebo",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive single dose of placebo day 1",
                    "interventionNames": [
                        "Drug: Drug: Placebo for ABBV-1088"
                    ]
                },
                {
                    "label": "Group 5- ABBV-1088 Dose E",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive single dose of ABBV-1088 dose E on day 1",
                    "interventionNames": [
                        "Drug: Drug: ABBV-1088"
                    ]
                },
                {
                    "label": "Group 5- Placebo",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive single dose of placebo day 1",
                    "interventionNames": [
                        "Drug: Drug: Placebo for ABBV-1088"
                    ]
                },
                {
                    "label": "Group 6- ABBV-1088 Dose F",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive single dose of ABBV-1088 dose F on day 1",
                    "interventionNames": [
                        "Drug: Drug: ABBV-1088"
                    ]
                },
                {
                    "label": "Group 6- Placebo",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive single dose of placebo day 1",
                    "interventionNames": [
                        "Drug: Drug: Placebo for ABBV-1088"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Drug: ABBV-1088",
                    "description": "\u2022 Oral Capsule",
                    "armGroupLabels": [
                        "Group 1- ABBV-1088 Dose A",
                        "Group 2- ABBV-1088 Dose B",
                        "Group 3- ABBV-1088 Dose C",
                        "Group 4- ABBV-1088 Dose D",
                        "Group 5- ABBV-1088 Dose E",
                        "Group 6- ABBV-1088 Dose F"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Drug: Placebo for ABBV-1088",
                    "description": "\u2022 Oral Capsule",
                    "armGroupLabels": [
                        "Group 1- Placebo",
                        "Group 2- Placebo",
                        "Group 3- Placebo",
                        "Group 4- Placebo",
                        "Group 5- Placebo",
                        "Group 6- Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Maximum Plasma Concentration (Cmax) of ABBV-1088",
                    "description": "Cmax of ABBV-1088",
                    "timeFrame": "Up to approximately 11 days"
                },
                {
                    "measure": "Time to Cmax (Tmax) of ABBV-1088",
                    "description": "Tmax of ABBV-1088",
                    "timeFrame": "Up to approximately 11 days"
                },
                {
                    "measure": "Terminal Phase Elimination Rate Constant (Beta) of ABBV-1088",
                    "description": "Terminal phase elimination rate constant (beta) of ABBV-1088",
                    "timeFrame": "Up to approximately 11 days"
                },
                {
                    "measure": "Terminal Phase Elimination Half-Life (t1/2) of ABBV-1088",
                    "description": "Terminal phase elimination half-life of ABBV-1088",
                    "timeFrame": "Up to approximately 11 days"
                },
                {
                    "measure": "Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-1088",
                    "description": "AUCt of ABBV-1088",
                    "timeFrame": "Up to approximately 11 days"
                },
                {
                    "measure": "Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-1088",
                    "description": "AUCinf of ABBV-1088",
                    "timeFrame": "Up to approximately 11 days"
                },
                {
                    "measure": "Number of Participants With Adverse Events (AEs)",
                    "description": "An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study",
                    "timeFrame": "Up to Day 32"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* BMI is \u2265 18.0 to \u2264 32.0 kg/m\\^2 after rounding to the tenths decimal at screening.\n* A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG\n\nExclusion Criteria:\n\n* History of cardiac disease, including congenital structural/conduction abnormalities, cardiomyopathy, myocardial infarction, cardiac arrhythmia.\n* History of or active medical condition(s) or surgical procedure(s) that might affect gastrointestinal motility, pH, or absorption \\[e.g., Crohn's disease, chronic GERD, celiac disease, gastroparesis, short bowel syndrome, gastric surgery (except pyloromyotomy for pyloric stenosis during infancy), cholecystectomy, vagotomy, bowel resection, etc.\\].\n* History of suicidal ideation within one year prior to study drug administration as evidenced by answering \"yes\" to questions 4 or 5 on the suicidal ideation portion of the C-SSRS completed at Screening, or any history of suicide attempts within the last two years.\n* History of any clinically significant neurological, respiratory (except mild asthma as a child), endocrine, metabolic, renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "65 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "ABBVIE CALL CENTER",
                    "role": "CONTACT",
                    "phone": "844-663-3742",
                    "email": "abbvieclinicaltrials@abbvie.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "ABBVIE INC.",
                    "affiliation": "AbbVie",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Acpru /Id# 264249",
                    "status": "RECRUITING",
                    "city": "Grayslake",
                    "state": "Illinois",
                    "zip": "60030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.34447,
                        "lon": -88.04175
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Related Info",
                    "url": "https://www.abbvieclinicaltrials.com/study/?id=M24-929"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        }
    },
    "hasResults": false
}